About CorMedix Inc.
https://www.cormedix.comCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
CEO
Joseph Todisco MBA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-03-26 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 121
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
D. Boral Capital
Buy
HC Wainwright & Co.
Buy
Needham
Buy
JMP Securities
Market Outperform
RBC Capital
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.69M
Value:$40.33M
VANGUARD GROUP INC
Shares:3.98M
Value:$28.2M
BLACKROCK INC.
Shares:3.55M
Value:$25.19M
Summary
Showing Top 3 of 206
About CorMedix Inc.
https://www.cormedix.comCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $104.28M ▲ | $41.73M ▲ | $108.56M ▲ | 104.11% ▲ | $1.42 ▲ | $57.31M ▲ |
| Q2-2025 | $39.74M ▲ | $18.33M ▲ | $19.83M ▼ | 49.9% ▼ | $0.29 ▼ | $20.52M ▼ |
| Q1-2025 | $39.08M ▲ | $17.36M ▲ | $20.64M ▲ | 52.82% ▲ | $0.32 ▲ | $20.82M ▲ |
| Q4-2024 | $31.21M ▲ | $17.1M ▲ | $13.46M ▲ | 43.14% ▲ | $0.22 ▲ | $13.61M ▲ |
| Q3-2024 | $11.46M | $14.06M | $-2.78M | -24.24% | $-0.05 | $-2.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $55.72M ▼ | $750.86M ▲ | $376.73M ▲ | $374.13M ▲ |
| Q2-2025 | $190.71M ▲ | $252.6M ▲ | $31.97M ▼ | $220.63M ▲ |
| Q1-2025 | $77.5M ▲ | $149.58M ▲ | $34.69M ▲ | $114.89M ▲ |
| Q4-2024 | $51.69M ▲ | $118.85M ▲ | $34.19M ▲ | $84.66M ▲ |
| Q3-2024 | $46.03M | $77.59M | $18.87M | $58.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $108.56M ▲ | $30.86M ▲ | $-291.32M ▼ | $150.53M ▲ | $-109.93M ▼ | $30.35M ▲ |
| Q2-2025 | $19.83M ▼ | $29.99M ▲ | $-20.21M ▼ | $83.24M ▲ | $93.02M ▲ | $29.97M ▲ |
| Q1-2025 | $20.64M ▲ | $19.74M ▲ | $-194.82K ▲ | $6.09M ▼ | $25.63M ▲ | $19.73M ▲ |
| Q4-2024 | $13.46M ▲ | $-5.61M ▲ | $-304.16K ▼ | $11.28M ▼ | $5.36M ▼ | $-5.62M ▲ |
| Q3-2024 | $-2.78M | $-13.65M | $6.32M | $14.07M | $6.75M | $-13.66M |
CEO
Joseph Todisco MBA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-03-26 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 121
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
D. Boral Capital
Buy
HC Wainwright & Co.
Buy
Needham
Buy
JMP Securities
Market Outperform
RBC Capital
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.69M
Value:$40.33M
VANGUARD GROUP INC
Shares:3.98M
Value:$28.2M
BLACKROCK INC.
Shares:3.55M
Value:$25.19M
Summary
Showing Top 3 of 206